Breast cancer
Conditions
Interventions
Lafutidine is administered orally at the dose of 10 mg twice daily for 8 weeks.
Sponsors
Yokohama City University
Yokohama Clinical Oncology Group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)breast cancer patient with taxane-induced peripheral neuropathy (>=Grade2), which continued more than 1 month 2)receiving chemotherapy and scheduled to receive same regimen 3)with digestive symptom such as upper abdominal discomfort by treatment 4)age: >=20 and =<75 5)expected more than 6 months survival 6)written informed consent
Exclusion criteria
Exclusion criteria: 1)with severe complications (such as liver failure, renal failure, heart failure) 2)with history of allergy 3)administration of Lafutidine within 2weeks before prior to treatment 4)receiving drugs to influence peripheral neuropathy 5)with peripheral neuropathy for other cause (such as severe edema, diabetes, vitamin B12 deficiency) 6)doctor's decision not to be registered to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The level of improvement of peripheral neuropathy is evaluated by Short-form McGill Pain Questionnaire(SF-MPQ), Patient Neurotoxity Questionnaire(PNQ) and CTCAE v4.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life, Safety | — |
Countries
Japan
Contacts
Public ContactTakashi Chishima
Yokohama City University Hospital Breast surgery
Outcome results
None listed